Prostate Cancer Immunotherapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

2016 • 29,943 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 • 14,809 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

2010 • 5,069 citations

PD-1 and Its Ligands in Tolerance and Immunity

2008 • 4,838 citations

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 • 3,044 citations

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1995 • 2,842 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

2010 • 2,721 citations

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

1999 • 2,574 citations

Paradoxical roles of the immune system during cancer development

2006 • 2,213 citations

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

2001 • 1,761 citations

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

2009 • 1,604 citations

Inflammation in prostate carcinogenesis

2007 • 1,548 citations

Cancer despite immunosurveillance: immunoselection and immunosubversion

2006 • 1,263 citations

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

2003 • 1,255 citations

Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

2006 • 1,069 citations

Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity

2005 • 972 citations

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

2010 • 947 citations

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

2009 • 882 citations

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

2004 • 742 citations

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

2008 • 639 citations

Improved Endpoints for Cancer Immunotherapy Trials

2010 • 519 citations

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

2004 • 476 citations

Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade

2005 • 465 citations

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

2000 • 421 citations

CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients

2006 • 416 citations

Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing

2008 • 400 citations

A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

2007 • 397 citations

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1997 • 383 citations

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers

2005 • 377 citations

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

2001 • 373 citations

618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target

2005 • 358 citations

CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer

2007 • 348 citations

Prostate cancer as a model for tumour immunotherapy

2010 • 346 citations

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

2009 • 296 citations

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

2005 • 279 citations

Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation

2004 • 258 citations

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

2008 • 242 citations

Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF

2009 • 241 citations

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients

2009 • 237 citations

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

2010 • 236 citations

Human prostate‐infiltrating CD8⁺ T lymphocytes are oligoclonal and PD‐1⁺

2009 • 227 citations

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy

1999 • 223 citations

Commentary on “Sipuleucel-T immunotherapy for castration-resistant prostate cancer”. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

2011 • 201 citations

Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy

2008 • 150 citations

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

2007 • 132 citations

Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters

2009 • 126 citations

Dominance of CD4⁺ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma

2007 • 112 citations

Tolerization of Tumor-Specific T Cells Despite Efficient Initial Priming in a Primary Murine Model of Prostate Cancer

2007 • 90 citations

Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

2010 • 86 citations

Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization

2004 • 80 citations

Cutting Edge: Tumor-Specific CD8+ T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells

2009 • 77 citations

Rapid tolerization of virus-activated tumor-specific CD8 ⁺ T cells in prostate tumors of TRAMP mice

2008 • 69 citations

Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells

2008 • 62 citations

Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)

2008 • 60 citations

Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC)

2009 • 56 citations